首页> 中文期刊> 《实用癌症杂志》 >参芪扶正注射液联合化疗治疗晚期胃癌的疗效观察

参芪扶正注射液联合化疗治疗晚期胃癌的疗效观察

         

摘要

目的 探讨参芪扶正注射液联合化疗治疗晚期胃癌患者的临床疗效.方法 回顾性分析96例Ⅲ~Ⅳ期晚期胃癌患者临床资料与治疗情况,其中化疗治疗者48例为对照组,化疗联合参芪扶正注射液治疗者48例为观察组.统计2组治疗4个疗程后的临床疗效、生存质量改善及不良反应情况.结果 观察组临床疾病控制率66.7%,与对照组62.5%比较,P>0.05;观察组生存质量改善率70.8%,明显高于对照组47.9%(P<0.05);观察组不良反应发生率明显低于对照组(P<0.05).结论 应用参芪扶正注射液联合化疗治疗Ⅲ~Ⅳ期晚期胃癌可明显降低不良反应发生率,提高其生存质量.%Objective To investigate the clinical efficacy of Shenqifuzheng injection combined with chemotherapy for ad -vanced gastric cancer .Methods Retrospectively analyzed the medical records of 96 cases of stage Ⅲ ~Ⅳ advanced gastric cancer and treatment information;wherein the chemotherapeutic treatment in 48 cases was the control group;SFI chemotherapy treatment in 48 cases was the observation group;clinical efficacy and adverse reactions ,quality of life after 4 courses were ana-lyzed.Results In the observation group ,clinical disease control rate was 66.7%,and 62.5%in the control group ,P>0.05;im-provement rate of the quality of life in the observation group was 70.8%,which was significantly higher than 47.9%,P<0.05;adverse reactions in the observation group was significantly lower than the control group ,P<0.05.Conclusion Shenqifuzheng injection combined with chemotherapy in the treatment of stage Ⅲ ~Ⅳadvanced gastric cancer can significantly reduce adverse reactions and improve their quality of life .

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号